Health
SRI has been a leader for decades in the development of tools, technologies, and therapeutics that have saved and improved countless lives around the world. Our Biosciences division works with government and commercial clients to seamlessly integrate basic and translational research, drug discovery, and nonclinical and clinical development.
-
SRI charts the future of bioscience in Arizona
Working with the Flinn Foundation, SRI created a roadmap that will guide Arizona’s ongoing transformation into a national bioscience hub.
-
How bioinformatics can improve mine management
SRI’s BioCyc platform is giving a bioinformatic startup an edge in mine-related research.
-
Global alliance drives AI healthcare innovation in Abu Dhabi
SRI aims to build a cutting-edge global hub to advance digital health transformation.
-
SRI receives FDA clearance to initiate a clinical trial of high-dose naloxone
Researchers say the new formulation could reduce overdose fatalities caused by fentanyl and other synthetic opioids.
-
Helping pre-teens get the sleep they need
The American Academy of Sleep Medicine highlights SRI research focused on the relationship between parental engagement and pre-teen sleep.
-
Can we put a hospital on wheels?
SRI is working on a mobile healthcare platform that aims to improve healthcare access and health outcomes across rural America.
-
Microbes make nutritious meals out of air
An SRI-led team has succeeded in creating a food product rich in essential nutrients, suitable for quickly scaling up disaster relief in remote locations.
-
Robots in the cleanroom
A global health leader is exploring how SRI’s robotic telemanipulation technology can enhance pharmaceutical manufacturing.
-
SRI selected as DARPA’s Regional Commercial Accelerator
DARPA looks to harness SRI’s expertise to speed up tech transition — out of the lab into the real world — and scale DARPA-funded technologies for U.S. national and economic security outcomes.
-
The naked mole rat may hold the key to new treatments for neurodegenerative diseases
SRI researchers study the cells of the long-living rodent to find new drug targets for Alzheimer’s, Parkinson’s, and other neurodegenerative disorders.
-
Engineered helper T cell could become a cancer killer
SRI scientists are developing a cell-based platform using an often-undervalued subset of helper T cells to deliver potent antitumor proteins for solid tumors, overcoming dose-related toxicities.
-
SRI identifies predictors of adolescent obesity
As part of a nationwide longitudinal study of adolescent brain development, researchers use AI to analyze data to pinpoint obesity risk factors.